Cost-effectiveness analyses of durvalumab consolidation therapy
versus no consolidation therapy after chemoradiotherapy in
stage-III NSCLC

J 2022

Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC

HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ a Miloslav KLUGAR

Základní údaje

Originální název

Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC

Autoři

HUSSAIN, Mohammad Salman (356 Indie, garant, domácí), Jitka KLUGAROVÁ (203 Česká republika, domácí) a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Lung Cancer, Clare, Elsevier Ireland Ltd. 2022, 0169-5002

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.300

Kód RIV

RIV/00216224:14110/22:00126341

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.lungcan.2022.06.002

UT WoS

000861749300002

Klíčová slova anglicky

Cost-effectiveness; Durvalumab; Lung cancer; Non-small-cell lung cancer; NSCLC; Systematic review

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2023 11:53, Mgr. Tereza Miškechová

Anotace

V originále

Background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. Economic studies from different parts of the world presented varying findings. Therefore, the objective of this study was to assess the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC. Methods PubMed, Embase, and Cochrane databases were searched till March 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC who had not progressed after chemoradiotherapy. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using the updated version of Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022) checklists. All costs were converted to 2022 US dollars ($) by adjusting for the gross domestic product (GDP) deflator index and purchasing power parities for GDP. Results A total of seven studies were found to be eligible for inclusion. The majority of studies were conducted in the US (n = 3), while one study each was conducted in China, Italy, Switzerland, and the UK. The healthcare payers’ perspective was most commonly observed among the included studies and the time horizon varied from 5 years to a lifetime. Three studies received funding from Industry. Four included studies used the Markov model, while two employed the semi-Markov model and, one study used decision-analytic model. The ICER of durvalumab consolidation therapy in the US was found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years (QALY). Likewise, the ICER of durvalumab in European countries ranged from $62,021 to $76,068 per QALY. The ICER was below the implemented country-specific willingness-to-pay thresholds in all the included studies. Conclusion Durvalumab consolidation therapy was found to be cost-effective compared to no consolidation therapy after chemoradiotherapy in stage-III NSCLC patients.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

LTC20031, projekt VaV

Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST

Citovat

HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ a Miloslav KLUGAR. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC. Lung Cancer. Clare: Elsevier Ireland Ltd., 2022, roč. 170, August 170, s. 11-19. ISSN 0169-5002. Dostupné z: https://dx.doi.org/10.1016/j.lungcan.2022.06.002.

@article{1883018,
   author = {Hussain, Mohammad Salman and Klugarová, Jitka and Klugar, Miloslav},
   article_location = {Clare},
   article_number = {August 170},
   doi = {http://dx.doi.org/10.1016/j.lungcan.2022.06.002},
   keywords = {Cost-effectiveness; Durvalumab; Lung cancer; Non-small-cell lung cancer; NSCLC; Systematic review},
   language = {eng},
   issn = {0169-5002},
   journal = {Lung Cancer},
   title = {Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC},
   url = {https://www.sciencedirect.com/science/article/pii/S0169500222004664},
   volume = {170},
   year = {2022}
}

TY  - JOUR
ID  - 1883018
AU  - Hussain, Mohammad Salman - Klugarová, Jitka - Klugar, Miloslav
PY  - 2022
TI  - Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
JF  - Lung Cancer
VL  - 170
IS  - August 170
SP  - 11-19
EP  - 11-19
PB  - Elsevier Ireland Ltd.
SN  - 01695002
KW  - Cost-effectiveness
KW  - Durvalumab
KW  - Lung cancer
KW  - Non-small-cell lung cancer
KW  - NSCLC
KW  - Systematic review
UR  - https://www.sciencedirect.com/science/article/pii/S0169500222004664
N2  - Background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. Economic studies from different parts of the world presented varying findings. Therefore, the objective of this study was to assess the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC. Methods PubMed, Embase, and Cochrane databases were searched till March 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC who had not progressed after chemoradiotherapy. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using the updated version of Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022) checklists. All costs were converted to 2022 US dollars ($) by adjusting for the gross domestic product (GDP) deflator index and purchasing power parities for GDP. Results A total of seven studies were found to be eligible for inclusion. The majority of studies were conducted in the US (n = 3), while one study each was conducted in China, Italy, Switzerland, and the UK. The healthcare payers’ perspective was most commonly observed among the included studies and the time horizon varied from 5 years to a lifetime. Three studies received funding from Industry. Four included studies used the Markov model, while two employed the semi-Markov model and, one study used decision-analytic model. The ICER of durvalumab consolidation therapy in the US was found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years (QALY). Likewise, the ICER of durvalumab in European countries ranged from $62,021 to $76,068 per QALY. The ICER was below the implemented country-specific willingness-to-pay thresholds in all the included studies. Conclusion Durvalumab consolidation therapy was found to be cost-effective compared to no consolidation therapy after chemoradiotherapy in stage-III NSCLC patients.
ER  -

HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ a Miloslav KLUGAR. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC. \textit{Lung Cancer}. Clare: Elsevier Ireland Ltd., 2022, roč.~170, August 170, s.~11-19. ISSN~0169-5002. Dostupné z: https://dx.doi.org/10.1016/j.lungcan.2022.06.002.

Podrobný výpis o publikaci